Xin Hua She·2025-11-22 03:17Core Insights - Bayer has established its first innovation center in China, located in the International Pharmaceutical Innovation Park in Beijing, aimed at fostering local pharmaceutical innovation and enhancing clinical research capabilities [1][2] - The park is part of a broader strategy to attract global pharmaceutical companies and create a collaborative ecosystem for drug development, with significant infrastructure already in place [2][3] Group 1: Bayer's Innovation Center - The Bayer Innovation Center will incubate local pharmaceutical companies and facilitate their international expansion [1] - The center aims to collaborate with high-level research and clinical institutions to improve basic research and clinical translation capabilities [1] Group 2: International Pharmaceutical Innovation Park - The park covers an area of 5.8 square kilometers and is divided into four functional zones: headquarters cluster, medical-engineering integration area, R&D transformation area, and pharmaceutical manufacturing area [2] - The existing built-up area of the park is 280,000 square meters, with ongoing construction of supporting facilities for pharmaceutical R&D [2] Group 3: Future Developments - By 2026, a new batch of leading innovative pharmaceutical and medical device companies is expected to settle in the park [3] - The park is also focusing on developing an AI healthcare industry cluster, with plans for key infrastructure such as a supercomputing base and trusted data spaces for the healthcare and pharmaceutical sectors [3]